Clinical Trials
88
52 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
51
58.0%
Completed
1
1.1%
Not yet recruiting
1
1.1%
Recruiting
34
38.6%
Withdrawn
1
1.1%
No approval data available
- Cleveland Clinic researchers developed the GARD model that uses tumor gene expression from ten radiosensitivity genes to calculate personalized radiation doses for HPV-positive throat cancer patients. - Analysis of 191 patients showed higher GARD scores correlated with better survival outcomes, and retrospective analysis identified 22% of patients who could maintain excellent outcomes with reduced radiation doses. - The genomic approach could help overcome the clinical impasse where standard 70 Gy doses cause severe side effects but previous attempts to reduce to 60 Gy have failed in trials. - This breakthrough represents a shift from one-size-fits-all radiation treatment toward precision medicine, potentially reducing treatment toxicity while maintaining cure rates of 80-95%.
- The phase 1b/2 OrigAMI-1 trial demonstrated that amivantamab monotherapy achieved a 22% objective response rate and 3.7-month median progression-free survival in advanced colorectal cancer patients. - Combination therapy with amivantamab plus FOLFOX or FOLFIRI showed enhanced efficacy with a 43% objective response rate and 7.4-month median progression-free survival in a smaller patient cohort. - Two phase 3 trials, OrigAMI-2 and OrigAMI-3, have been launched to further evaluate amivantamab versus cetuximab in metastatic colorectal cancer patients with RAS and BRAF wild-type status. - The bispecific antibody's trifunctional mechanism targeting EGFR and MET receptors, plus immune cell-directed activity, positions it as a potential improvement over current anti-EGFR therapies for the 50% of metastatic colorectal cancer patients eligible for treatment.
